Leflunomide, malononitriloamides, and transplantation immunology
- 31 July 1998
- journal article
- Published by Elsevier in Transplantation Reviews
- Vol. 12 (3) , 156-164
- https://doi.org/10.1016/s0955-470x(98)80022-0
Abstract
No abstract availableThis publication has 39 references indexed in Scilit:
- REGULATION OF B CELL FUNCTION BY THE IMMUNOSUPPRESSIVE AGENT LEFLUNOMIDE1Transplantation, 1996
- PHARMACOLOGICALLY INDUCED REGRESSION OF CHRONIC TRANSPLANT REJECTIONTransplantation, 1995
- Blood Distribution and Single-Dose Pharmacokinetics of LeflunomideTherapeutic Drug Monitoring, 1995
- Dihydroorotate Dehydrogenase Is a High Affinity Binding Protein for A77 1726 and Mediator of a Range of Biological Effects of the Immunomodulatory CompoundJournal of Biological Chemistry, 1995
- Inhibition of Interleukin 2 (IL-2)-stimulated tyrosine kinase activity by leflunomideInflammation Research, 1994
- LEFLUNOMIDE IN EXPERIMENTAL TRANSPLANTATIONTransplantation, 1994
- Effects of leflunomide (HWA 486) on expression of lymphocyte activation markersInflammation Research, 1993
- Therapeutic effects of leflunomide, a new antirheumatic drug, on glomerulonephritis induced by the antibasement membrane antibody in ratsClinical Immunology and Immunopathology, 1991
- Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejectionInflammation Research, 1991
- Leflunomide (HWA 486) inhibits experimental autoimmune tubulointerstitial nephritis in ratsInternational Journal of Immunopharmacology, 1989